Multi-User Equipment approved in grant 13/07600-3: Omnilog phenotypic microarray

• Grant number: 19/07606-8
• Support type: Multi-user Equipment Program
• Duration: July 01, 2019 - June 30, 2026
• Field of knowledge: Biological Sciences - Biophysics - Molecular Biophysics
• Principal researcher: Glaucius Oliva
• Grantee: Glaucius Oliva
• Home Institution: Instituto de Física de São Carlos (IFSC). Universidade de São Paulo (USP). São Carlos , SP, Brazil
• Associated research grant: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery, AP.CEPID
• EMU web page: Página do Equipamento Multiusuário não informada
• Type of equipment: Caracterização e Análises de Amostras - Biomédica - Celular; Caracterização e Análises de Amostras - Proteínas/Ácidos nuclêicos - Arrays
• Manufacturer: Fabricante não informado
• Model: Modelo não informado

Abstract

The Center for Innovation in Biodiversity and Drug Discovery (CIBFar) is a joint initiative resulting from existing collaborative research projects, including the Physics Institute of São Carlos (IFSC) and the School of Pharmaceutical Sciences of Ribeirao Preto at the University of São Paulo (USP), the Institute of Chemistry at the State University of São Paulo (UNESP), the Institute of Chemistry at the State University of Campinas (UNICAMP), and the Department of Chemistry at the Federal University of São Carlos (UFSCar). The major goals of this Center are to perform basic and applied science and to develop technologies, such as in vitro and in vivo biological and pharmacological evaluations, for all areas of biodiversity and drug discovery that rely on state-of-the-art methods in medicinal chemistry, natural products chemistry, synthetic organic chemistry, and molecular and structural biology. Strategic partnerships with the private sector are always sought, particularly with national and international pharmaceutical companies and research institutes within the health sector. The ultimate goals are the development of clinical candidates for tropical infectious diseases, cancer and central nervous system disorders and the development of new synthetic routes to generic drugs. On the educational front, the Center also relies on the considerable experience that has been acquired over the last eleven years from our previous CEPID-FAPESP. Intensive work has been done on outreach programs focused on science education from elementary school to high school. CIBFar has the benefit of joining research groups in a modern multidisciplinary setting while also providing access to a well-established infrastructure with extensive experience in the areas of technical, financial, educational, technological and executive management. (AU)